Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles

Authors

Alexandra Rodzinski, Herbert Wertheim College of Medicine, Florida International UniversityFollow
Rakesh Guduru, Herbert Wertheim College of Medicine and College of Engineering, Florida International UniversityFollow
Ping Liang, University of California, Riverside; Cellular Nanomed Inc.
Ali Hadjikhani, Department of Electrical and Computer Engineering, Florida International UniversityFollow
Tiffanie Stewart, Herbert Wertheim College of Medicine, Florida International UniversityFollow
Carolyn Runowicz, Herbert Wertheim College of Medicine, Florida International UniversityFollow
Richard Cote, University of Miami
Norman Altman, University of Miami
Ram Datar, University of Miami
Sakhrat Khizroev, Herbert Wertheim College of Medicine and Department of Electrical and Computer Engineering, Florida International UniversityFollow

Date of this Version

2-15-2016

Document Type

Article

Abstract

It is a challenge to eradicate tumor cells while sparing normal cells. We used magnetoelectric nanoparticles (MENs) to control drug delivery and release. The physics is due to electric-field interactions (i) between MENs and a drug and (ii) between drug-loaded MENs and cells. MENs distinguish cancer cells from normal cells through the membrane’s electric properties; cancer cells have a significantly smaller threshold field to induce electroporation. In vitro and in vivo studies (nude mice with SKOV-3 xenografts) showed that (i) drug (paclitaxel (PTX)) could be attached to MENs (30-nm CoFe₂O₄@BaTiO₃ nanostructures) through surface functionalization to avoid its premature release, (ii) drug-loaded MENs could be delivered into cancer cells via application of a d.c. field (~100 Oe), and (iii) the drug could be released off MENs on demand via application of an a.c. field (~50 Oe, 100 Hz). The cell lysate content was measured with scanning probe microscopy and spectrophotometry. MENs and control ferromagnetic and polymer nanoparticles conjugated with HER2-neu antibodies, all loaded with PTX were weekly administrated intravenously. Only the mice treated with PTX-loaded MENs (15/200 μg) in a field for three months were completely cured, as confirmed through infrared imaging and post-euthanasia histology studies via energy-dispersive spectroscopy and immunohistochemistry.

Comments

Originally published in Scientific Reports.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Recommended Citation

Rodzinski, Alexandra; Guduru, Rakesh; Liang, Ping; Hadjikhani, Ali; Stewart, Tiffanie; Runowicz, Carolyn; Cote, Richard; Altman, Norman; Datar, Ram; and Khizroev, Sakhrat, "Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles" (2016). Electrical and Computer Engineering Faculty Publications. 40.
https://digitalcommons.fiu.edu/ece_fac/40